This observational cohort study (n=30) evaluated the safety and efficacy of Ibogaine-Magnesium Therapy in veterans with sequelae of repeated blast exposure. Conducted by Stanford University, the study focuses on assessing the impact of this therapy on veterans who have experienced traumatic brain injury (TBI) and associated complications like PTSD, depression, and anxiety. Participants, male veterans aged 18-70 with a history of head trauma or blast exposure, were observed before and after receiving the treatment.
The study aims to provide a better understanding of the potential benefits and risks of Ibogaine-Magnesium Therapy, which remains under-researched despite its use among veterans seeking alternative treatments. The primary outcome measure is the change in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) scores from baseline to immediately post-treatment and at a one-month follow-up. The safety profile will be evaluated through the assessment of unexpected or serious adverse events. This study, which began in November 2021, is estimated to complete by February 2024. It’s significant as it addresses the urgent need for effective treatments for veterans suffering from the long-term effects of combat-related TBI.
Trial Details
Trial Number
Sponsors & Collaborators
Stanford UniversityResearchers at Stanford are exploring the potential of ketamine, MDMA and psilocybin by connecting neuroscience, psychiatry and anesthesiology.
Papers
Magnesium–ibogaine therapy in veterans with traumatic brain injuriesThis observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.